Scientific deep-dive
Contrave for Keeping Weight Off: The Maintenance Data
A small randomized trial found less weight regain on Contrave than placebo after a meal-replacement program, though people still regained weight. Here is what that trial and the longer post hoc data show, and why they don’t settle life after a GLP-1.
Contrave slowed weight regain in the first trial built to test it after a behavior program, but it did not stop it. Among 89 adults randomized after a 6-month meal-replacement program, people on naltrexone-bupropion regained 4.24 kg over the next 6 months, against 7.70 kg on placebo (p = 0.047), and 46% vs 19.5% met the trial’s definition of maintaining weight (p = 0.0159)[1]. That is an encouraging small trial with real limits, and it asks a narrower question than the one most people bring to it: what happens if you take Contrave to hold on to weight you lost on a GLP-1? No trial has tested that.
About this article
This page looks only at keeping weight off. For how the drug works and how much weight it removes in the first place, see our Contrave evidence review.
What the maintenance trial did
The study, published in Clinical Obesity in 2026, ran at bariatric centers of excellence in Ontario and is registered as NCT04589130[1]. It enrolled adults with a BMI of at least 27 and, per the registry entry, at least one weight-related condition, who had lost at least 5% of their weight in a 6-month intensive behavior program with meal replacements. Their mean loss before the trial began was 16 kg, about double the 8 kg the authors say behavioral programs typically report[1].
Participants were randomized to Contrave (n = 44) or placebo (n = 45), with both groups receiving dietary and psychosocial counseling. The dose reached the full 32 mg/360 mg by week 4 and continued to week 28. After that, everyone took Contrave open-label through week 52, so the placebo group crossed over and the second half had no control arm[1].
| Measure | Contrave + counseling | Placebo + counseling | p value |
|---|---|---|---|
| Weight regain | +4.24 kg | +7.70 kg | 0.047 |
| Maintained weight | 46% | 19.5% | 0.0159 |
| Randomized / completed blinded phase | 44 / 37 | 45 / 41 or 42 | Not applicable |
How to read those numbers
The abstract says treatment “prevented weight regain,” yet the Contrave group gained an average of 4.24 kg, roughly a quarter of the 16 kg lost beforehand[1]. The fair summary is less regain than placebo. Several features of the report argue for caution on top of that.
- The sample is small and the main result is close to the line. Only 89 people were randomized, most of them White and female, and the authors list this as a limitation[1]. A p value of 0.047 leaves little margin, and the statistical methods describe no adjustment for testing three primary endpoints[1].
- The analysis population isn’t named. The paper states no estimand and doesn’t say how missing weights were handled. By our arithmetic, 46% and 19.5% match about 17 of 37 and 8 of 41 completers, which suggests a completer analysis, though the paper doesn’t say so[1]. Its text and flow diagram also differ slightly on the number who completed each phase.
- The groups started a little differently. Weight lost before randomization averaged 16.9% in the Contrave group and 14.8% on placebo[1]. The authors describe baseline characteristics as similar.
- Two of the three primary endpoints aren’t given in the text. The registered primaries were mean percentage weight change, the share who maintained weight, and the share who lost 5% or more[1]. The paper’s text and figure captions give figures in kilograms and for the maintenance outcome only, while one bar chart shows the weight categories.
- There are no adverse event counts. The results text reports weight outcomes but not adverse event rates; it records only that 25 people stopped over the year, 6 of them for reasons related to the study drug[1]. People with major depression, seizure history or significant psychiatric illness were excluded[1].
- The open-label half can’t carry much weight. After crossover, the authors say the former placebo group’s regain “appears to have been mitigated,” and they saw no further loss[1]. With no control group and no numbers in the text, that remains an observation.
On funding, Bausch Health Canada paid for the study and supplied the tablets, and Currax Pharmaceuticals funded the medical writing. The paper says the funder had no role in trial design or conduct, and the authors declare no conflicts[1].
The longer-term data: larger, but post hoc
The longest figures come from le Roux 2022, a post hoc analysis of six trials and 10,198 participants. It selected people who had lost at least 5% or 10% by week 16 and asked how many stayed at or above that threshold[2]. In the LIGHT cardiovascular outcomes trial, 44.4% on naltrexone-bupropion vs 34.2% on placebo held a 5% loss at week 208 (P<0.001). For 10% loss, the rates were 41.6% vs 25.3% and the difference was not significant (P = 0.11)[2].
Selecting early responders after randomization breaks the balance randomization creates, and people who lost 5% by week 16 on placebo may differ from those who did so on the drug. The authors acknowledge post hoc drawbacks and missing later data, and two authors worked for Bausch Health, one for Currax, with funding from Orexigen and Bausch Health Canada[2]. Read this as support for a hypothesis about long-term maintenance, not as proof of it.
A different kind of maintenance data comes from Grilo 2023, an NIH-supported double-blind trial of 66 people with binge-eating disorder and obesity who had responded to initial treatment. Over 16 weeks, intention-to-treat binge remission was 68.8% on naltrexone-bupropion and 50.0% on placebo, a difference that was not statistically significant overall (p = 0.14), and 22% vs 3% reached at least 5% further weight loss[3]. Its population limits how widely this applies.
Long trials show the weight holds on average, but the numbers depend on who is counted
The 56-week phase 3 trials give indirect support. In COR-II, mean weight change was -6.5% at week 28 and -6.4% at week 56 on the 32 mg/360 mg dose, compared with -1.9% and -1.2% on placebo, so the average stayed flat between those points[4]. That comes from a modified intent-to-treat analysis carrying forward the last on-drug weight. People with under 5% loss were re-randomized between weeks 28 and 44 to stay on this dose or move to a higher one, so the week 56 figure was reweighted and excluded those who moved up[4]. These participants lost the weight on the drug, a different situation from starting it after a diet.
How much a figure depends on the analysis shows clearly in COR-BMOD, which paired the drug with intensive behavior modification. Its 56-week weight loss on the drug was 9.3% in the modified intent-to-treat analysis, 11.5% among completers and 7.8% across all randomized participants; on placebo, the same three figures were 5.1%, 7.3% and 4.9%[5]. A 2026 pooled analysis limited to people who completed a phase 3 trial reported -9.5% vs -2.7% at week 56, with an on-treatment approach and several authors reporting ties to Currax[6]. Completer figures tend to run higher than what an average person starting treatment can expect.
Dropout is the practical problem for any maintenance plan. In the main obesity trials described in the label, 46% on Contrave and 45% on placebo withdrew before week 56, most within the first 12 weeks, and 24% vs 12% stopped because of an adverse reaction[7]. Common effects are covered in our guide to Contrave side effects.
What about keeping off weight lost on a GLP-1?
There is no trial that answers this. The maintenance trial’s authors say their results cannot necessarily be extended to weight lost with obesity medications and name that as future work[1]. Anyone comparing options should also note how differently the GLP-1 maintenance trials were designed. In those, patients who lost weight on the drug were randomized to continue it or switch to placebo.
| Trial | Lost weight with | Randomized to | Change after randomization |
|---|---|---|---|
| Chetty 2026 (Contrave) | Meal replacement and behavior program; mean 16 kg | Contrave vs placebo for 28 weeks | +4.24 kg vs +7.70 kg |
| STEP 4 (semaglutide 2.4 mg) | Semaglutide, 20-week run-in; mean 10.6% | Continue vs placebo for 48 weeks | -7.9% vs +6.9% |
| SURMOUNT-4 (tirzepatide 10 or 15 mg) | Tirzepatide, 36-week lead-in; mean 20.9% | Continue vs placebo for 52 weeks | -5.5% vs +14.0% |
The results come from Chetty 2026[1], STEP 4[8] and SURMOUNT-4[9]. The published abstracts of the two GLP-1 trials report these numbers without naming an estimand. Differences between the injectables and placebo are numerically larger, but the units, baselines and participants differ, and the injectable trials are withdrawal studies. They show what stopping does, which we cover in what happens when you stop semaglutide. They can’t show whether switching to Contrave would slow that regain.
Two smaller findings bear on the choice. In a New Zealand observational study of people with low response to a meal-replacement program who were offered liraglutide or naltrexone-bupropion for 13 weeks, only 24% of the 46 completers lost at least 5%, and only 18 of those who accepted a drug took naltrexone-bupropion[10]. A diet program’s poor responders may not do as well as those who entered the Ontario trial, which required at least 5% loss[1]. And in a 12-week randomized trial of 101 telehealth patients, adding a behavioral program to naltrexone-bupropion produced 1.8 kg more loss than the drug alone (p = 0.03), in a study mostly authored by employees of the program’s owner[11]. That was a weight-loss trial, not a maintenance one.
What the label says
CONTRAVE is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition.— Contrave prescribing information, Section 1 (DailyMed version published November 2025)
So maintenance sits inside the US indication, for adults who meet those criteria[7]. The label also has a stopping rule: response should be evaluated after 12 weeks at the maintenance dosage, and if a patient has not lost at least 5% of baseline body weight, Contrave should be discontinued[7]. That rule fits awkwardly with someone starting the drug at a plateau, because the people in the maintenance trial averaged regain, not further loss[1]. The trial report doesn’t address it, so it’s worth asking a prescriber directly how they would judge success.
What to raise with a prescriber
- What counts as working. Ask what weight range and timeline would justify continuing, given the label’s 12-week, 5% rule[7].
- Whether it is safe for you. The label carries a boxed warning on suicidal thoughts and behaviors, and contraindicates uncontrolled hypertension, seizure disorders, other bupropion products, bulimia or anorexia, chronic opioid use and recent MAOI use[7]. Blood pressure and heart rate need monitoring[7].
- How you lost the weight. The trial covered a meal-replacement and behavior program with ongoing counseling[1]. If you lost weight on a GLP-1 or after surgery, say so, since this evidence does not cover you.
- Whether counseling continues. Both arms in the maintenance trial kept receiving dietary and psychosocial counseling, so the result does not describe taking the pill alone[1].
Frequently Asked Questions
References
- 1.Chetty VT, Denescu L, Zevin B, Damjanovic S, Balodis IM, Elsharif A, Foster G. Effect of Naltrexone HCl and Bupropion HCl (Contrave) Extended-Release Tablet (NB-ER) for Weight Maintenance in Adult Patients After a 6-Month Intensive Behaviour Modification Program Combined With Meal Replacements. Clin Obes. 2026. PMID: 42479940.
- 2.le Roux CW, Fils-Aimé N, Camacho F, Gould E, Barakat M. The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy. EClinicalMedicine. 2022. PMID: 35747175.
- 3.Grilo CM, Lydecker JA, Gueorguieva R. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial. Psychol Med. 2023. PMID: 37366017.
- 4.Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, Kim D, Dunayevich E, COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013. PMID: 23408728.
- 5.Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011. PMID: 20559296.
- 6.Kushner RF, Iceta S, Tronieri JS, Still CD, Fitch A, Apovian CM. Fixed-dose, extended-release combination of naltrexone and bupropion reduces craving and body weight: A pooled post hoc analysis. Obes Res Clin Pract. 2026. PMID: 42642275.
- 7.Nalpropion Pharmaceuticals LLC. CONTRAVE (naltrexone hydrochloride and bupropion hydrochloride) extended-release tablets. Prescribing information. DailyMed, National Library of Medicine. 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=485ff360-32c8-11df-928b-0002a5d5c51b
- 8.Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D, STEP 4 Investigators. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021. PMID: 33755728.
- 9.Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, Ahmad NN, Zhang S, Liao R, Bunck MC, Jouravskaya I, Murphy MA, SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024. PMID: 38078870.
- 10.Shand J, Jiang Y, Murphy R. Outcomes of obesity medications in those with low response to a low-energy diet meal replacement programme: An observational study. Obes Pillars. 2026. PMID: 41551724.
- 11.Jones RA, Lee AM, Foster GD, Nadolsky S, Killion K, Gentry LN, Zeldman J, Hong YR, Medcalf A, Estes F, Richardson KM, Cardel MI. Efficacy of Oral Antiobesity Medications With Versus Without Adjunct Behavioral Weight Management Treatment. Obesity (Silver Spring). 2026. PMID: 41703970.
Related research
Contrave Side Effects (2026): What's Common, What's Serious & How to Manage Them
Contrave (naltrexone/bupropion), which is not a GLP-1, most often causes nausea, constipation, headache and insomnia. Serious FDA-label risks include a boxed warning for suicidal thoughts, seizures, higher blood pressure and liver injury.
11 min read
Does Contrave Reduce Cravings? What a 2026 Pooled Analysis Found
A 2026 pooled post hoc analysis of phase 3 completers found Contrave improved craving control and some food cravings more than placebo. Here is what the numbers show, why the completer design matters, and what the label says.
7 min read
Naltrexone for Weight Loss + How Contrave Actually Works: Evidence Review
Naltrexone alone is not FDA-approved for weight loss. Contrave (naltrexone plus bupropion) is, and produced -6.1% mean weight loss at 56 weeks in the COR-I trial. How it works, how it compares with Wegovy and Zepbound across trials, and who it suits.
14 min read
Does Bupropion Cause Weight Loss? Honest Evidence Review
Bupropion causes modest weight loss but is not FDA-approved for obesity on its own. In Anderson 2002, completers on 300 or 400 mg/day plus diet counseling lost 7.2% and 10.1% at 24 weeks vs 5.0% on placebo. Contrave, the approved combination, gave 6.1% at 56 weeks.
12 min read
Wellbutrin XL for Weight Loss: How Fast and How Much? (Evidence Review)
Wellbutrin XL is not FDA-approved for weight loss, but bupropion is the one antidepressant tied to weight loss rather than gain. Off-label trials showed about 4.4 kg at 26 weeks. Boxed warning for suicidality under age 25; not for seizure disorders or eating disorders.
13 min read
How to Get Contrave Online (2026): The Oral Naltrexone-Bupropion Pathways & Cost
Contrave is an FDA-approved oral weight-loss pill (naltrexone-bupropion ER), not a GLP-1. This guide covers the legitimate online pathways, 2026 cost by pathway, how to verify a telehealth provider, the contraindications, and the boxed warning for suicidal thoughts.
11 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Found
Medication-included compounded GLP-1 on 28-day cash plans, plus insurance help for brand-name GLP-1s
Read full review →From $289/4 wks
billed per 4 weeks
Oak
Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up
Read full review →From $200/mo
starting dose
From $99/mo